- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00435578
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
April 28, 2009 updated by: Threshold Pharmaceuticals
An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma
The primary objectives of this study are:
- To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate
- To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC
The secondary objectives are:
- To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive SCLC as measured by duration of response, progression-free survival and overall survival
- To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard (IPM)
The exploratory objectives of this trial are:
- To evaluate the effect of glufosfamide on lung cancer symptoms
- To evaluate the role of tumor cell glucose transporter expression on the efficacy of glufosfamide
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Greenbrae, California, United States, 94904
- California Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age
- Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/IEC
- Documented extensive SCLC with progression occurring at least 60 days after completion of first-line therapy (sensitive disease)
- Measurable disease by RECIST criteria (at least one target lesion; no target lesion may have received radiotherapy within 6 weeks of study start)
- A minimum of 21 days between prior radiation therapy, immunotherapy, or other anti-tumor therapy and study entry
- Recovered from reversible toxicities of prior therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
- Hemoglobin ≥ 9.0 g/dL, ANC ≥ 1,500/µL, platelets ≥ 100,000/µL
- Total bilirubin ≤ 1.5-fold ULN
- AST/ALT ≤ 2.5-fold ULN (≤ 5-fold ULN if liver metastases)
- Creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula)
- All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose
Exclusion Criteria:
- More than one previous chemotherapy regimen
- Concomitant or planned hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for SCLC other than protocol therapy
- Limited stage SCLC (defined as confined to one hemithorax including ipsilateral supraclavicular lymph nodes and excluding pleural effusion)
- Symptomatic brain metastases requiring corticosteroids
- Active clinically significant infection requiring antibiotics
- Known HIV positive or active hepatitis B or C
- Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, congestive heart failure, or stroke
- Other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past 5 years
- Major surgery within 28 days of the start of study treatment, without complete recovery
- Females who are pregnant or breast-feeding
- Participation in an investigational drug or device study within 28 days of the first day of dosing on this study
- Concomitant disease or condition that could interfere with the conduct of the study, or that, in the opinion of the investigator, could pose an unacceptable risk to the subject in this study.
- Unwillingness or inability to comply with the study protocol for any other reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gerold Bepler, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator: John C Ruckdeschel, MD, Barbara Ann Karmanos Cancer Institute
- Principal Investigator: Peter D Eisenberg, MD, California Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
February 13, 2007
First Submitted That Met QC Criteria
February 14, 2007
First Posted (Estimate)
February 15, 2007
Study Record Updates
Last Update Posted (Estimate)
April 30, 2009
Last Update Submitted That Met QC Criteria
April 28, 2009
Last Verified
April 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Hypersensitivity
- Lung Neoplasms
- Carcinoma
- Small Cell Lung Carcinoma
- Carcinoma, Small Cell
Other Study ID Numbers
- TH-CR-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Small Cell Lung
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
Clinical Trials on Glufosfamide
-
Eleison Pharmaceuticals LLC.Threshold PharmaceuticalsCompletedSoft Tissue SarcomaUnited States
-
Eleison Pharmaceuticals LLC.Terminated
-
European Organisation for Research and Treatment...Completed
-
European Organisation for Research and Treatment...CompletedBrain and Central Nervous System TumorsFrance, Switzerland, Italy, Israel, Netherlands, Portugal, Austria, Greece
-
European Organisation for Research and Treatment...CompletedPancreatic CancerFrance, Switzerland, Israel, Germany, Netherlands, Denmark, Greece
-
Threshold PharmaceuticalsPPDCompletedPancreatic CancerUnited States, Brazil, Ukraine, India, Russian Federation, Romania, Hungary, Mexico, Argentina, Bulgaria, Czech Republic
-
Eleison Pharmaceuticals LLC.RecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Threshold PharmaceuticalsPPDCompletedNeoplasms | Pancreatic NeoplasmsUnited States, Brazil